United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$243.27 USD
-4.59 (-1.85%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $243.24 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UTHR 243.27 -4.59(-1.85%)
Will UTHR be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
Other News for UTHR
Merck hits all-time high after FDA nod for lung disease therapy
United Therapeutics Corp (UTHR) CEO Martine Rothblatt Sells 30,000 Shares
United Therapeutics' Robust Portfolio Fuels Double-Digit Growth
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
Merck wins FDA approval of sotatercept for rare lung disease